Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Cyprotex provides support to drug discovery projects at AstraZeneca

Cyprotex (LSE: CRX) today announces a new agreement with AstraZeneca to provide essential information on compounds from their drug discovery projects.

The agreement will make use of Cyprotex's Cloe Screen™ in vitro technology which cost-effectively profiles new compounds for a variety of properties that affect their ability to be processed by the body. Cyprotex will deliver data regarding the potential absorption of AstraZeneca's compounds through the gut - essential information to assess their suitability as drugs that will be administered in pill form. The assay is performed on batches of up to 94 compounds at a time to deliver information on the amount of compound that permeates through the gut wall, whether it is pumped back in again and classification of the compounds into high, medium or low permeability. This is useful information for prioritising the best compounds to promote through the next stages of drug development - saving time and money by enabling an early focus on compounds with the greatest potential to succeed as drugs.

AstraZeneca selected Cyprotex following a series of focussed evaluations of Cyprotex's technology. Ongoing work will involve analysis of monthly batches of compounds over a six-month period. Cyprotex already supports drug discovery projects at AstraZeneca's M�lndal site in Sweden.

Robert Atwater, Cyprotex Chief Executive Officer, commented: "We are pleased to be expanding our relationship with AstraZeneca to support additional therapeutic areas at different sites within the organization. It is a great a tribute to the calibre of our scientific team and our technology to have been selected by AstraZeneca to supply this important information on their discovery compounds."

For further information:

Robert Atwater, Chairman and Chief Executive
Cyprotex plc

Tel: +44 (0) 1625 505100

Henry Harrison-Topham / Heather Salmond
Bankside Consultants Limited

Tel: +44 (0) 20 7444 4141

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): 888-297-7683
Europe: +44 1625 505100


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.